Author:
Solano-Iturri G.,García-Jiménez N.,Solano-Iturri J.D.,Blanco-Sampascual S.
Reference9 articles.
1. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease;Rostom;Gastroenterology,2006
2. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. 2013 [consultado 1 Mar 2014]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm
3. Sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers – the plot thickens;Lebwohl;Aliment Pharmacol Ther,2014
4. Systematic review: Sprue-like enteropathy associated with olmesartan;Ianiro G1;Aliment Pharmacol Ther,2014
5. Severe spruelike enteropathy associated with olmesartan;Rubio-Tapia;Mayo Clin Proc,2012
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Olmesartan medoxomil;Reactions Weekly;2018-02